P. Heinrich Stahl (Author/Editor) studied Pharmaceutical Sciences in Freiburg, Germany, and completed his Ph. D. thesis on the synthesis of purine heterocycles under the supervision of Kurt Walter Merz. This was followed by a postdoctoral fellowship at the Sloan-Kettering-Institute for Cancer Research, New York. In 1969, he joined in Basel, Switzerland. At CIBA, Basel, Switzerland, he focused his attention on pharmaceutical technology and solved problems in tablet granulate drying. Subsequent to the merger of the Ciba and Geigy companies, he built up the Preformulation Group for API characterization at the interface between medicinal chemistry, dosage form development, and analytics. After an assignment to the Summit, N.J., research site of Ciba-Geigy, he returned to Basel to take over the responsibility for special formulation topics. Since 1995 he was responsible for the global coordination of early compound evaluation. After his retirement in 1997, he still continues his research at the Biocenter in Basel, focusing on the in vitro modeling of passive drug transport across lipid double-layers. Dr. P. H. Stahl is an IUPAC Fellow and a member of the International Association for Pharmaceutical Technology, of the Pharmaceutical Society of Germany, and of the Swiss Society of Industrial Pharmacists. He has co-authored multiple scientific and technological papers, patents, and book chapters. He is an active consultant to several pharmaceutical companies. Camille G. Wermuth (Author/Editor) PharmD, PhD, Founder, President and Chief Scientific Officer of Prestwick Chemicalis, a former Professor of Organic and Medicinal Chemistry at the Faculty of Pharmacy at the Louis Pasteur University in Strasbourg, France. Pr. Wermuth's research combines synthesis and molecular modeling, and concentrates mainly on CNS diseases. He is the author and co-author of over 300 peer-reviewed scientific papers and of several books or book chapters, and holds over 60 patents. Pr. Wermuth has been awarded the Charles Mentzer Prize of the Societe Francaise de Chimie Therapeutique, the Leon Velluz Prize of the French Academy of Science, and the Prix de l'Ordre des Pharmaciens by the French Academy of Pharmacy. He is Corresponding Member of the German Pharmaceutical Society, and was nominated Commandeurs des Palmes Academiques. He has been nominated President of the Division of Chemistry and Human Health of the International Union of Pure and Applied Chemistry (IUPAC).
...the editors have produced a rare commodity, a body of knowledge on an important area, summarized in single volume.In a nutshell, this long-overdue volume belongs on the personal shelf of every pharmaceutical scientist working with new chemical entities. (Pharmaceutical Development and Technology)